UKINETS2018 Poster Presentations (1) (28 abstracts)
The impact of 68Ga-based PET-CT scanning on the management of patients with sporadic pancreatic neuroendocrine tumours (pNETs)
Daniel Cuthbertson 1 , Jorge Barriuso 2 , Michail Pizanais 3 , Matthew Jaffa 1 , Angela Lamarca 2 , Gillian Vivian 3 , Tom Halloran 1 , Tom Westwood 2 , Andreas Prachalias 3 , Derek O’Reilly 2 , Hulya Weismann 4 , Wendy Martin 3 , Sobhan Vinjamuri 4 , D Mark Pritchard 5 , Richard Hubner 2 , Raj Srirajaskanthan 3 , John Ramage 3 , Mike Raraty 4 , Paula Ganeh 4 , Steve Fenwick 1 , Juan Valle 2 & Vincent Yip 4
1University Hospital Aintree, Liverpool, UK; 2Christie Hospital, Manchester, UK; 3King’s College Hospital, London, UK; 4Royal Liverpool University Hospital, Liverpool, UK; 5Royal Liverpool University Hospital, London, UK.
Background: Pancreatic neuroendocrine tumours (panNETs) are rare tumours (prevalence 4/100,000). Diagnosis and staging of panNETs requires biochemical screening, cross-sectional imaging (with CT/MRI), endoscopic ultrasound (EUS) and where available, functional imaging using 68Ga-labelled synthetic octreotide analogues using PET-CT due to its reported higher sensitivity and specificity.
Methods: A retrospective, electronic case note study was carried out across three ENETS Centres (Liverpool, Aintree, Royal Liverpool; The Christie, Manchester; and King’s College Hospital, London) to investigate the effect of 68Ga-based PET-CT imaging on patient management, in patients with a clinically-suspected or histologically-confirmed sporadic panNET. Patients who had undergone a 68Ga-based PET-CT scan for a panNET were identified using a prospectively populated list.
Results: A total of 172 patients were identified between 2014 and 2018; 52% male, 48% female; with a median age of 68 years (range 13–89). Of these 90% (n=153) were still alive (17 (10%) had died; 2(1%) missing data); 83% (n=132) had non-functional tumours (based on their biochemical profile) and 17% (n=27) had functional tumours (8%, 13 missing data). A confirmed histological diagnosis (from either biopsy/surgical resection) was available in 91% of patients (n=156) with imaging only in the remainder. Of patients with histology available 51% (n=73) were Grade (G)1 tumours, 46% (n=66) were G2 and 3% (n=5) were G3; 55% (n=93) had localised disease; 18% (n=31) were locally advanced and 27% (n=46) were metastatic. Indications for performing a 68Ga-PET-CT included diagnosis and staging 36% (n=62), consideration for peptide receptor radionuclide therapy (PRRT) 9% (n=15) and post-operative assessment or clinical surveillance to look for disease recurrence 55% (n=93). In 54% of cases (n=75) the evidence provided by the gallium scan was confirmatory and consistent with other imaging findings, in 12% (n=17) it resulted in a change of treatment and in 28% (n=39) new sites of disease were identified not evident with other imaging techniques. Overall it was deemed to result in a change in management in 39% of cases.
Conclusion: 68Ga-based PET-CT imaging in patients with panNETs changes clinical management in 39% of cases by providing supplementary information informing the diagnosis, staging, most appropriate treatment modality and subsequent monitoring of recurrence.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more